论文部分内容阅读
为了增加难治性急性髓细胞白血病(AML)对阿糖胞苷(Ara-C)的敏感性,作者对于13例AML患者试用小剂量Ara-C(LD-Ara-C)并用粒细胞集落刺激因子(G-CSF)疗法。13例AML患者年龄17～70岁(中数46岁),FAB分类:M_01例,M_13例,M_24例,M_5al例,继发于恶性淋巴瘤的AML2例(其中1例系继发于骨髓增生异常综合征(MDS)演变来的AML],低增生性白血病1例,伴三系MDS的初发性AML(AML/TMDS)1例。13例中3例初治,10例系复发患者既往曾用BHAC-DMP方案化疗或骨髓移植治疗。治疗方法为Ara-C 20mg/d,持续静滴,疗效不明显可增至40～
In order to increase the sensitivity of refractory acute myeloid leukemia (AML) to cytarabine (Ara-C), the authors used a small dose of Ara-C (LD-Ara-C) in the presence of granulocyte colony stimulation in 13 patients with AML. Factors (G-CSF) therapy. 13 patients with AML aged 17 to 70 years (median 46 years old), FAB classification: M_01 cases, M_13 cases, M_24 cases, M_5al cases, 2 cases of AML secondary to malignant lymphoma (1 case was secondary to myeloproliferative Abnormality syndrome (MDS) evolved from AML], 1 case of hypoproliferative leukemia, 1 case of primary AML (AML/TMDS) with MDS of the triline, 3 cases of 13 cases with initial treatment, 10 cases of relapsed patients After treatment with BHAC-DMP regimen or bone marrow transplantation, the treatment was Ara-C 20mg/d, continuous intravenous infusion, the efficacy was not obvious can be increased to 40~